Aim: To evaluate the efficacy and safety of ipragliflozin vs placebo as add-on therapy to metformin and sitagliptin in Korean patients with type 2 diabetes mellitus (T2DM).
| INTRODUCTION
Diabetes presents a considerable burden to patients, their families, and public health systems worldwide. In 2015, the International Diabetes Federation (IDF) estimated there were 415 million cases of diabetes and an additional 318 million adults with impaired glucose tolerance worldwide. 1 In Korea, it was estimated that~4.8 million people aged ≥30 years had type 2 diabetes mellitus (T2DM) in 2014, 2 almost doubling the observed incidence in 2013. 3 In line with the IDF guidelines, the Korean Diabetes Association guidelines recommend managing T2DM with an initial therapy of metformin, in conjunction with lifestyle modification. 4, 5 Dual therapy may be considered if patients' initial glycated haemoglobin (HbA1c) level is ≥7.5% or if the HbA1c target is not achieved within 3 months of initiating metformin monotherapy. 4, 5 If inadequate glycaemic control persists with dual therapy, a third agent with a complementary action may be added. 5 Because increased insulin resistance and diminishing β-cell function tend to occur with T2DM progression, antidiabetic agents that target components of the glucose metabolism pathway may become less effective over time. 6 Agents that work via alternative biological processes will ultimately be essential for chronic disease management. Sodium-glucose co-transporter-2 (SGLT2) inhibitors act via the kidney to inhibit SGLT2, and thereby suppress renal glucose uptake, resulting in urinary glucose excretion. 7 The unique mechanism of SGLT2 inhibitors complements the actions of other antidiabetic agents to reduce hyperglycaemia, making them suitable for use as part of combination regimens in patients with T2DM, regardless of the degree of insulin resistance and β-cell dysfunction. 8 There is considerable interest in the combined use of SGLT2 inhibitors with dipeptidyl peptidase-4 (DPP-4) inhibitors for effective glycaemic control without an increased potential for hypoglycaemia, weight gain or cardiovascular diseases. 8, 9 Randomized studies have demonstrated the efficacy and safety of triple therapy using a SGLT2
inhibitor, a DPP-4 inhibitor, and metformin in patients who have inadequately controlled T2DM. 10, 11 Ipragliflozin has been shown to be efficacious and well tolerated both as a monotherapy 12, 13 and in dual therapy with metformin or DPP-4 inhibitors [14] [15] [16] [17] [18] ; however, no study has investigated the effects of ipragliflozin added to metformin and a DPP-4 inhibitor. In the present paper, we report the findings from a phase III, randomized, placebo-controlled study, which compared the efficacy and safety of ipragliflozin against placebo as an add-on therapy to metformin and sitagliptin in Korean patients with inadequately controlled T2DM.
| METHODS

| Study design
This was a double-blind, randomized, parallel-group, placebo-controlled, multi-centre, phase III study conducted at 22 sites in Korea between 2015 and 2017 (ClinicalTrials.gov identifier: NCT02452632).
The study comprised a 2-week single-blind placebo run-in period, followed by a 24-week double-blind treatment period, and a 4-week follow-up period. The study protocol and other relevant study documents were reviewed and approved by the institutional review board at each study site. The study was conducted in compliance with the principles of the Declaration of Helsinki, the International Conference on Harmonization Harmonized Tripartite Guideline for Good Clinical
Practice, and the applicable local laws and regulations. All patients provided written informed consent prior to study enrolment.
| Study population
Inclusion criteria included: age 19 to 74 years (inclusive); confirmed T2DM diagnosis; stable diet and exercise programme ≥8 weeks prior to study participation; treatment with metformin at ≥1500 mg/day (or ≥1000 mg/day at the investigator's discretion) and sitagliptin at 100 mg/day for at least 8 weeks prior to study participation; HbA1c 
| Treatments
Eligible patients were randomly assigned to receive ipragliflozin (50 mg/day) or placebo as an add-on therapy to metformin and sitagliptin. Randomization was stratified by study site and HbA1c level (≥8.0% or <8.0%) using a computer-generated randomization schedule. Assignment of study medications was blinded to all patients, investigators and the sponsor. To maintain blinding, the packaging and appearance of medications used in this study were identical and no urinary glucose measurements were permitted during the study, unless deemed necessary for safety reasons. 
| Study endpoints
The primary efficacy endpoint was the change in HbA1c from baseline to end of treatment (EOT). Secondary efficacy endpoints included changes in FPG, body weight, fasting serum insulin (FSI), and waist circumference from baseline to EOT, and the percentage of patients achieving the HbA1c targets (<6.5% and <7.0%) at EOT. Exploratory endpoints were changes in homeostatic model assessment of insulin resistance (HOMA-IR) and β-cell function (HOMA-β) from baseline to EOT. Key safety endpoints included the incidence of treatmentemergent adverse events (TEAEs) and TEAEs leading to discontinuation and changes in vital signs and clinical laboratory variables from baseline to EOT. TEAEs were defined as adverse events (AEs) that were observed after the first administration of the study medication for the treatment period.
| Statistical analyses
The sample size was calculated based on results from three previous studies: (1) dapagliflozin add-on to sitagliptin and metformin
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; (2) dapagliflozin add-on to metformin 20 ; and (3) ipragliflozin add-on to metformin. 15 Assuming the difference for changes in HbA1c from baseline to EOT between the ipragliflozin and placebo groups would be −0.45%
with an SD of 0.80, approximately 67 patients per treatment group would be required to detect superiority of ipragliflozin to placebo with 90% power and a significance level of 5% for a two-sided test. Assuming 5% of patients do not meet the criteria for the full analysis set (FAS),~140 randomized patients would be required for this study.
The FAS consisted of randomized patients who received at least one dose of the study medication, and had at least one post-baseline measurement. The per-protocol set (PPS) was a subgroup of the FAS and consisted of eligible patients who received the study medication for the entire treatment period, received metformin and sitagliptin for ≥56 days, had a compliance rate with the study medication of ≥80%, did not use prohibited concomitant medications, and did not have any clinically significant protocol deviations. The safety analysis set (SAF)
consisted of all patients who received at least one dose of the study medication during the treatment period.
Efficacy analyses were performed on the FAS population. Sensitivity analyses for HbA1c and FPG were repeated on the PPS population. Safety analyses were performed on the SAF. The mean differences in efficacy endpoints between the ipragliflozin and 3 | RESULTS
| Patient demographics and baseline characteristics
A total of 237 patients entered the study. Of these, 143 patients were randomized to receive ipragliflozin (n = 74) or placebo (n = 69). After randomization, 30 patients discontinued from the study and 113 patients (ipragliflozin: 56; placebo: 57) completed the 24-week treatment. The flow of patients through the study and reasons for discontinuation are summarized in Figure 1 . The most commonly reported reason for discontinuation in the ipragliflozin group was urinary glucose measurements (n = 9), whereas worsening of disease (n = 4) and consent withdrawal (n = 3) were the most common rea- reductions from baseline to EOT remained significantly greater with ipragliflozin than placebo (Table S1 ). Significantly more patients in the ipragliflozin group had HbA1c <7.0% at EOT compared with placebo (44.4%; 32/72 vs 12.1%; 8/66; P < .0001). Similarly, a significantly higher proportion of patients in the ipragliflozin group had HbA1c
<6.5% at EOT than the placebo group (12.5%; 9/72 vs 1.5%; 1/66; P = .0183). The results for HbA1c in the PPS population were similar to those in the FAS population (data not presented). and −0.64 (3.80) cm, respectively, with an adjusted mean difference of −1.44 cm (95% CI −2.78, −0.10; P = .0354).
| Secondary efficacy outcomes
In the ipragliflozin group FSI decreased significantly from baseline to EOT compared with the placebo group. The corresponding mean (SD) changes were − 1.14 (4.62) μU/mL and 0.08 (4.18) μU/mL, 
| Safety
A summary of TEAEs is provided in Table 2 . The incidence of TEAEs and drug-related TEAEs was similar across groups. The majority of the TEAEs were mild or moderate in severity. No deaths were reported in this study. The incidence of TEAEs leading to permanent discontinuation was low in both groups (6.8% in the ipragliflozin group and 2.9% in the placebo group). The most common TEAEs were nasopharyngitis and urticaria (4.1% each) in the ipragliflozin group and nasopharyngitis (7.4%) in the placebo group. There were no reports of hypoglycaemia, genital infection, volume depletion, and ketoacidosis in the ipragliflozin group. Incidences of urinary tract infection and polyuria/pollakiuria were low in both groups (ipragliflozin: 2.7% and 1.4%, respectively vs placebo: 1.5% for both). 
| DISCUSSION
In this study of Korean patients with T2DM inadequately controlled by metformin and sitagliptin, the addition of ipragliflozin significantly add-on to metformin and a DPP-4 inhibitor. These studies demonstrated favourable decreases in glycaemic variables and body weight following the addition of an SGLT2 inhibitor. 10, 11 In a randomized phase III study of patients with T2DM whose condition was inadequately controlled by metformin plus saxagliptin, addition of 10 mg/day dapagliflozin significantly reduced HbA1c levels, FPG levels, and body weight compared with placebo. Dapagliflozin add-on also led to significantly more patients achieving HbA1c target than placebo. 10 Similarly, in another randomized phase III study of patients inadequately controlled by metformin and linagliptin, addition of 10 mg/day empagliflozin significantly reduced HbA1c, FPG and body weight compared with placebo at the end of the 24-week treatment. 11 These findings provide evidence for the benefits of using SGLT2 inhibitors as an add-on in triple oral therapy to improve glycaemic control in patients inadequately controlled by metformin and DPP-4 inhibitors, with the added advantage of body weight reduction.
In the present study, we observed significant reduction in insulin resistance (HOMA-IR) and a trend towards improved β-cell function (HOMA-β) with ipragliflozin add-on therapy compared with placebo after 24 weeks of treatment. Previous studies of ipragliflozin monotherapy and ipragliflozin add-on to metformin have shown improvements in insulin resistance and β-cell function at the EOT. 14, 21 In a study in which patients were treated with ipragliflozin monotherapy, significant reductions in HOMA-IR levels and significant increases in HOMA-β levels from baseline were observed at the end of the 12-week treatment. 21 In another study in patients whose T2DM was inadequately controlled by metformin, addition of ipragliflozin resulted in significant decrease in HOMA-IR levels compared with placebo after 24 weeks of treatment. HDL levels at EOT. 15, 16 Consistent with the findings of these studies, the present study showed slight improvements in BP, and TG and HDL levels with the addition of ipragliflozin. These findings demonstrate the potential of ipragliflozin to improve BP and lipid variables in addition to glycaemic variables in patients with T2DM.
The addition of SGLT2 inhibitors to dual oral therapy has been reported to be well tolerated in patients with inadequate glycaemic control after treatment with metformin and DPP-4 inhibitors. 10, 11 The overall incidence of AEs and the incidence of discontinuations because of AEs were similar between the SGLT2 inhibitor add-on group and the placebo group. Hypoglycaemia was infrequent in both groups. 10, 11 In line with the results of these randomized studies, the present study showed that the addition of ipragliflozin to metformin and sitagliptin was well tolerated, with no previously unreported safety concerns identified and no increased risk of hypoglycaemia compared with placebo. Recent evidence suggested the potential risk of developing diabetic ketoacidosis with SGLT2 inhibitors; 24, 25 however, no incidence of ketoacidosis was observed in our study.
A limitation of the present study was the relatively short study duration, which precluded assessment of the longer-term efficacy and safety of ipragliflozin add-on therapy in this population. The sample size used in our study was also relatively small. Although triple therapy with an SGLT2 inhibitor added on to metformin plus a DPP-4 inhibitor has been reported in previous studies, this is nevertheless the first study to investigate the effects of ipragliflozin added to metformin and a DPP-4 inhibitor, and it provides important insights into the additional beneficial effects of ipragliflozin as an add-on to metformin and sitagliptin in Korean patients. Future research may focus on defining the long-term outcomes and safety profile of ipragliflozin add-on therapy in a broader patient population, alongside other SGLT2 inhibitors.
In conclusion, the addition of ipragliflozin to metformin and sitagliptin therapy in Korean patients with inadequately controlled T2DM resulted in significant improvements in glycaemic control compared with placebo. The improvement was associated with significant decreases in body weight and insulin resistance, with no observed or tolerability concerns compared with placebo. Ipragliflozin add-on therapy represents a valuable treatment option for patients failing on dual therapy with metformin and sitagliptin, particularly those who have concerns about weight gain or hypoglycaemia.
